Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoimmunotherapy Followed by Radiotherapy for ES-SCLC
NCT06479473Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Jun 2024
- Primary completion
- Mar 2025
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in small cell lung cancer (SCLC) (2 arms), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Progression-free Survival at 3 years. Started Jun 2024; status: recruiting.
02
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06479473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06479473.